SRPT Stock Down After EMA Places Clinical Hold on DMD Gene Therapy

Shares of Sarepta Therapeutics (SRPT) dropped more than 6% yesterday after the EMA placed a clinical hold on all studies evaluating Elevidys, its one-shot gene therapy for Duchenne muscular dystrophy (DMD). The therapy has been developed in collaboration with pharma giant Roche (RHHBY) .This hold has been placed in response to a patient’s death post-treatment with Elevidys, which was reported last month. Though the death was due to acute liver failure (a known risk of Elevidys), Sarepta believes that the pa ...